Ipsen's Bylvay has failed to meet its primary endpoint in the Phase 3 BOLD trial for biliary atresia, a rare pediatric liver disease, undermining hopes for a major label expansion in this high‑need population. The BOLD trial, involving 254 patients across 19 countries, aimed to show improved native liver survival versus placebo at 104 weeks, but Bylvay did not demonstrate this benefit despite maintaining its established safety profile. The setback compounds pressure on Ipsen’s Albireo portfolio, which was acquired for $952 million and already saw the pruning of other pipeline assets amid slower-than-expected momentum in rare‑liver indications. Financially, Bylvay remains a key revenue driver with more than €180 million in 2025 sales, but the biliary‑atresia failure raises questions about the long‑term growth potential of the Albireo platform and could prompt strategic reassessment by Ipsen. Sources: Ipsen's Bylvay Fails Phase 3 BOLD Trial In Rare Pediatric Liver Disea...
- Get link
- X
- Other Apps